Submit Your Article CMED MEACR meeting
An official publication of the Middle-Eastern Association for Cancer Research
Clinical Cancer Investigation Journal
ISSN Print: 2278-1668, Online: 2278-0513
ARTICLE
Year: 2020   |   Volume: 9   |   Issue: 3   |   Page: 75-78     View issue

Investigation of prostate cancer associated with prevalence


, ,
Abstract

Context: Prostate cancer (PCa) incidence rates (IRs) are highly variable worldwide. Aims: The aim was to evaluate the period prevalence (PP) and IRs of PCa in Isfahan/Iran. Materials and Methods: Data from March 24, 2011, to March 19, 2015, were obtained from the Isfahan Cancer Registry. PCa was distinguished by the related established topography code (C61). IRs and PP were calculated and expressed per 100 000 males. Statistical Analysis Used: The statistical analyses of dBase were performed using Microsoft Excel and SPSS version 20 (IBM Corp., Chicago, IL, USA) for windows. Results: Over a period of study, there were 1648 males that were identified with PCa. For the total population, the PP was calculated as 65.2/100,000 males. Histologically, of the total population studied, 99% reported adenocarcinoma that majority of them had mild or moderate gleason score. According to available information monographic code M with no definition regarding to subtype showed code 81140 as generally named adenoma (n = 1156), code 8000 generally named neoplasm (n = 468), transitional cell papilloma (n = 9), and acinar cell adenoma (n = 5). IRs were calculated for each year, that is, 2011–2012, 2012–2013, 2013–2014, and 2014–2015, as 14.5, 17.4, 15.5, and 17.8 (per 100,000 males), respectively. The mean (standard deviation, min-max) age of the patients was 72.0 (10.6, 16–110) years. In relation to the age of the study population, PCa occurred in 84% of patients aged >60 years. Conclusions: The number of deaths versus alive in patients with PCa was 583 versus 1065, respectively. Further studies toward pharmacotherapy management and genetic and environmental factors in PCa carcinogenesis recommended to be clarified in Iran.

Cite this article
Vancouver
Tadayon F, Tolou-Ghamari Z, Norouzi S. Investigation of prostate cancer associated with prevalence. Clin Cancer Investig J. 2020;9(3):75-8. https://doi.org/10.4103/ccij.ccij_104_19
APA
Tadayon, F., Tolou-Ghamari, Z., & Norouzi, S. (2020). Investigation of prostate cancer associated with prevalence. Clinical Cancer Investigation Journal, 9(3), 75-78. https://doi.org/10.4103/ccij.ccij_104_19

Copyright © 2024 Clinical Cancer Investigation Journal
Online since 01 December, 2011
Creative Commons License 
ISSN Print: 2278-1668, Online: 2278-0513